[F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study.

Purpose: To investigate the predictive value of 2-[18F]-fluoro-2-deoxy-D-glucose ([F]FDG) PET/CT for evaluating primary tumor (PT) and lymph node (LN) responses after neoadjuvant programmed death-ligand 1 (PD-L1) blockade monotherapy in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC).

Methods: In the single-arm phase 1b NATION-1907 trial (NCT04215471), 23 patients with LA-ESCC received two cycles of neoadjuvant PD-L1 blockade Adebrelimab followed by surgery. Among these, 18 patients underwent [F]FDG PET/CT scans both before immunotherapy and prior to surgery.

Comparative benefits of Ki and SUV images in lesion detection during PET/CT imaging.

Background: Clinical application of the tracer net influx rate (Ki) imaging in PET/CT remains limited, due to a lack of evidence demonstrating the superiority of Ki images in lesion detection, and guidelines on when to utilize Ki images. This study aims to compare the benefits of Ki and standardized uptake value (SUV) images in lesion detection during PET/CT imaging. By analyzing the performance of both techniques in identifying tumor lesions, the study seeks to provide guidance for the clinical application of Ki images.

One-tenth-activity total-body positron emission tomography versus full-activity imaging in patients with a complex of hepatic malignant tumors: a retrospective study.

Background: The value of ultra-low-activity 2-[F]-fluoro-2-deoxy-D-glucose (F-FDG) positron emission tomography (PET) imaging in patients with hepatic malignancies remains unclear.

Methods: A cross-sectional study was conducted from April 2019 to May 2021 in Zhongshan Hospital, Fudan University. A total of 49 patients with hepatic malignancies, including hepatocellular carcinoma (HCC) (n=13) or intrahepatic cholangiocarcinoma (ICC) (n=36), underwent 60-min dynamic PET imaging, with 15 undergoing full-activity F-FDG and 34 undergoing ultra-low-activity F-FDG.

Different hydration protocols for the quantification of healthy tissue uptake of half-dose F-FDG total-body positron emission tomography-computed tomography: a prospective study.

Background: This study aimed to investigate the effects of the volume and time of hydration on the quantification of healthy tissue uptake for 2-deoxy-2-[F]-fluoro-D-glucose (F-FDG) total-body positron emission tomography (PET)-computed tomography (CT) with half-dose activity.

Methods: This study prospectively enrolled 180 patients who underwent a total-body PET-CT scan 10 min after injection of a half-dose (1.85 MBq/kg) of F-FDG.

Development and Validation of PET/CT-Based Nomogram for Preoperative Prediction of Lymph Node Status in Esophageal Squamous Cell Carcinoma.

Purpose: This study was conducted to predict the lymph node status and survival of esophageal squamous cell carcinoma before treatment by PET-CT-related parameters.

Methods: From January 2013 to July 2018, patients with pathologically diagnosed ESCC at our hospital were retrospectively enrolled. Completed esophagectomy and two- or three-field lymph node dissections were conducted.

An exploration of the feasibility and clinical value of half-dose 5-h total-body F-FDG PET/CT scan in patients with Takayasu arteritis.

Purpose: To explore the feasibility and clinical value of 5-h delayed F-fluorodeoxyglucose (F-FDG) total-body (TB) positron emission tomography/computed tomography (PET/CT) in patients with Takayasu arteritis (TA).

Methods: This study included nine healthy volunteers who underwent 1-, 2.5-, and 5-h triple-time TB PET/CT scans and 55 patients with TA who underwent 2- and 5-h dual-time TB PET/CT scans with 1.

Ultralow-dose [F]FDG PET/CT imaging: demonstration of feasibility in dynamic and static images.

Objectives: Validation of [F]FDG PET/CT at ultralow-dose (0.37 MBq/kg) and compared to imaging at half-dose (1.85 MBq/kg).

Half-dose versus full-dose 18 F-FDG total-body PET/CT in patients with colorectal cancer.

Purpose: The purpose of this study was to investigate image quality and lesion detectability of half-dose (1.85 MBq/kg) 18 F-fluorodeoxyglucose (FDG) total-body positron emission tomography/computed tomography (PET/CT) for colorectal cancer, full-dose (3.7 MBq/kg) 18 F-FDG serving as a reference.

Investigating ultra-low-dose total-body [18F]-FDG PET/CT in colorectal cancer: initial experience.

Purpose: This study was to evaluate the effects of an ultra-low dose of [18F]-FDG on the image quality of total-body PET/CT and its lesion detectability in colorectal cancer (CRC).

Methods: Sixty-two CRC patients who underwent total-body PET/CT (uEXPLORER, United Imaging Healthcare, Shanghai, China) with an ultra-low dose (0.37 MBq/kg) of [18F]-FDG were enrolled in this retrospective study.

Holographic particle sizing and locating by using Hilbert-Huang transform.

By using the Hilbert-Huang transform, a novel method is proposed to perform the task of particle sizing and axial locating directly from in-line digital holograms rather than reconstructing the optical field. The intensity distribution of the particle hologram is decomposed into intrinsic mode functions (IMFs) by the empirical mode decomposition. From the Hilbert spectrum of these IMFs, the axial location of the particle can be calculated by fitting the spectrum to a straight line, and the particle size can be derived from the singularities of the spectrum.